Needed: Clean Sound Eggs

Consumer demand for clean fresh eggs, plus the high speed handling and packaging equipment used by processors emphasize the need for structurally sound eggs. The authors list suggestions for the egg producers

Solving the radial Dirac equations: a numerical odyssey

We discuss, in a pedagogical way, how to solve for relativistic wave functions from the radial Dirac equations. After an brief introduction, in Section II we solve the equations for a linear Lorentz scalar potential, V_s(r), that provides for confinement of a quark. The case of massless u and d quarks is treated first, as these are necessarily quite relativistic. We use an iterative procedure to find the eigenenergies and the upper and lower component wave functions for the ground state and then, later, some excited states. Solutions for the massive quarks (s, c, and b) are also presented. In Section III we solve for the case of a Coulomb potential, which is a time-like component of a Lorentz vector potential, V_v(r). We re-derive, numerically, the (analytically well-known) relativistic hydrogen atom eigenenergies and wave functions, and later extend that to the cases of heavier one-electron atoms and muonic atoms. Finally, Section IV finds solutions for a combination of the V_s and V_v potentials. We treat two cases. The first is one in which V_s is the linear potential used in Sec. II and V_v is Coulombic, as in Sec. III. The other is when both V_s and V_v are linearly confining, and we establish when these potentials give a vanishing spin-orbit interaction (as has been shown to be the case in quark models of the hadronic spectrum).Comment: 39 pages (total), 23 figures, 2 table

Explorations, Vol. 2, No. 3

Cover image: Ezra Pound Dedication: With affection and respect, this issue of EXPLORATIONS is dedicated to Carroll Terrell, Professor Emeritus of English. Articles include: Carroll Terrell and the Great American Poetry Wars, by Burton Hatlen Adventures in China, by H.Y. Forsythe, Jr. Harry Kern and the Making of the New Japan, by Howard B. Schonberger From the Dispatch Case: update on malnutrition in Maine, by Richard Cook Changing Approaches to Protein Structure Determination, by Robert Anderegg The Search of Effective Policy: Meeting the Challenge of an Aging Society, by Dennis A. Watkins and Julia M. Watkins Citizen Survey of the Maine State Police, by Robert A. Stron

Utilization and Outcomes of Single and Dual Kidney Transplants from Older Deceased Donors in the United Kingdom

BACKGROUND AND OBJECTIVES: Kidneys from elderly deceased donors are often discarded after procurement if the expected outcomes from single kidney transplantation are considered unacceptable. An alternative is to consider them for dual kidney transplantation. We aimed to examine the utilization of kidneys from donors aged ≥60 years in the United Kingdom and compare clinical outcomes of dual versus single kidney transplant recipients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data from the United Kingdom Transplant Registry from 2005 to 2017 were analyzed. We examined utilization rates of kidneys retrieved from deceased donors aged ≥60 years, and 5-year patient and death-censored graft survival of recipients of dual and single kidney transplants. Secondary outcomes included eGFR. Multivariable analyses and propensity score analysis were used to correct for differences between the groups. RESULTS: During the study period, 7841 kidneys were procured from deceased donors aged ≥60 years, of which 1338 (17%) were discarded; 356 dual and 5032 single kidneys were transplanted. Donors of dual transplants were older (median, 73 versus 66 years; P<0.001) and had higher United States Kidney Donor Risk Indices (2.48 versus 1.98; P<0.001). Recipients of dual transplants were also older (64 versus 61 years; P<0.001) and had less favorable human leukocyte antigen matching (P<0.001). After adjusting for confounders, dual and single transplants had similar 5-year graft survival (hazard ratio, 0.81; 95% CI, 0.59 to 1.12). No difference in patient survival was demonstrated. Similar findings were observed in a matched cohort with a propensity score analysis method. Median 12-month eGFR was significantly higher in the dual kidney transplant group (40 versus 36 ml/min per 1.73 m(2); P<0.001). CONCLUSIONS: Recipients of kidneys from donors aged ≥60 years have similar 5-year graft survival and better graft function at 12 months with dual compared with single deceased donor kidney transplants

A new approach to prevention of knee osteoarthritis: reducing medial load in the contralateral knee

Background. Few if any prevention strategies are available for knee osteoarthritis (OA). In those with symptomatic medial OA, the contralateral knee may be at high risk of disease and a reduction in medial loading in that knee might prevent disease or its progression there. Lateral wedge insoles reduce loading across an affected medial knee but their effect on the contralateral knee is unknown. Methods: To determine the proportion of persons with medial knee OA who had concurrent medial contralateral OA or developed contralateral medial OA later, we examined knee radiographs from the longitudinal Framingham Osteoarthritis Study. Then, to examine an approach to reducing medial load in the contralateral knee, 51 people from a separate study with painful medial tibiofemoral OA underwent gait analysis wearing bilateral controlled shoes with i) no insoles ii) two types of lateral wedge insoles laterally posted by 5 degrees. Primary outcome was the external knee adduction moment (EKAM) in the contralateral knee. Non-parametric confidence intervals were constructed around the median differences in percentage change in the affected and contralateral sides. Results: Of Framingham subjects with medial radiograph knee OA, 137/152 (90%) either had concurrent contralateral medial OA or developed it within 10 years. 43/67 (64%) of those with medial symptomatic knee OA had or developed the same disease state in the contralateral knee. Compared to a control shoe, medial loading was reduced substantially on both the affected (median percentage EKAM change =-4.84%; 95% CI -11.33% to -0.65%) and contralateral sides (median EKAM percentage change -9.34% (95% CI -10.57% to -6.45%). Conclusions: In persons with medial OA, the contralateral knee is also at high risk of medial OA. Bilateral reduction in medial loading in knees by use of strategies such as lateral wedge insoles might not only reduce medial load in affected knees but prevent knee OA or its progression on the contralateral side

Maine Blueberry Advisory Committee Research Report

The 1990 edition of the Maine Blueberry Advisory Committee Research Reports was prepared for the Maine Wild Blueberry Commission and the University of Maine Wild Blueberry Advisory Committee by researchers with the Maine Agricultural Experiment Station and Maine Cooperative Extension Service at the University of Maine, Orono. Projects in this report include: 1. Biology and action thresholds of secondary blueberry pests 2. Control of blueberry maggot 3. Control of secondary blueberry pests 4. Application of steam as a method of controlling secondary pest insects on lowbush blueberry: a feasibility study 5. Pollination of the lowbush blueberry by native bees 6. Nitrogen-phosphorus study 7. Potassium study 8. Multiple cropping of wild stands 9. Phosphorus dose/response curve 10. Improvement in the color and texture of the canned blueberry 11. The effect of fertilization and irrigation on blueberry fruit quality 12. Investigation of preprocess changes (chemical, microbiological, and/or physical) that could lead to the development of a simple and inexpensive method to measure preprocess berry spoilage 13. The effect of postharvest handling on the dietary fiber and ellagic acid content of lowbush blueberries 14. Determination of pesticide residue levels in freshly harvested and processed lowbush blueberries 15. Evaluation of Defoliating Diseases 16. Vacuum Sanitation for Disease Control 17. Evaluation and modification of commercial herbicide applications 18. Evaluation of the suitability of remote sensing to evaluate plant cover in lowbush blueberry fields 19. Evaluation of Sethoxydin (POAST) in lowbush blueberry fields 20. Seedling pruning study 21. Evaluation of norflurazon (SOLICAM) with or without hexazinone (VELPAR) for bunchberry control 22. Selective wiper and mechanical control of dogbane and bracken fern 23. Evaluation of norflurazon (SOLICAM) in fall vs spring for oatgrass control 24. Evaluation of sulfonyl urea herbicides for bunchberry control 25. Evaluation of postemergence applications of DPX-L5300 for bunchberry control 26. Effect of time of application and formulation of hexazinone (VELPAR) on blueberry and bunchberry 27. Investigations of lowbush blueberry fruit-bud cold hardiness 28. The economics of investing in irrigation for lowbush blueberries 29. Effects of irrigation on lowbush blueberry yield and quality 30. Groundwater and surface water development for blueberry irrigation 31. Design, fabrication and testing of an experimental sterilizer for blueberry field

1993-94 Progress Report

The 1993 edition of the Progress Reports was prepared for the Maine Wild Blueberry Commission and the University of Maine Wild Blueberry Advisory Committee by researchers at the University of Maine, Orono. Projects in this report include: 1. Effects of irrigation on lowbush blueberry yield and quality 2. The Economics of investigating irrigation for lowbush blueberries 3. Phosphorus dose/response curve 4. Winter injury protection by potassium 5. Multiple cropping of wild stands 6. Effect of Boron and Calcium on lowbush blueberry fruit set and yield 7. Comparison of N, NP, and NPK fertilizers to correct nitrogen and phosphorus deficiency 8. Determination of pesticide residue levels in freshly harvested and processed lowbush blueberries 9. Effects of calcium salts and citric acid on the quality of canned lowbush blueberries 10. Investigation of preprocess changes (chemical, microbiological, and/or physical) that can lead to the development of a simple and inexpensive method to measure preprocess berry spoilage 11. The effect of fertilization and irrigation in blueberry fruit quality 12. Pollination Ecology of lowbush blueberry in Maine 13. Current importance of insects in lowbush blueberry fields 14. Application of heat as a method of controlling secondary pest insects on lowbush blueberry: a feasibility study 15. Control of blueberry maggot 16. Control of secondary blueberry pest insects 17. Biology and action thresholds of secondary blueberry pest insects 18. Cold-hardiness of native lowbush blueberry 19. Design, fabrication, and testing of an experimental sterilizer for blueberry fields 20. Canned Product Quality--Heat-resistant molds 21. Sanitation for disease control 22. Evaluation of Velpar® impregnated DAP and Pronone® for weed control 23. Evaluation of postemergence applications of tribenuron methyl for bunchberry control 24. Evaluation of postemergence applications of a tank mix of tribenuron methyl and hexazinone for bunchberry control 25. Thresholds of dogbane and bracken fem by mechanical and chemical control in lowbush blueberry fields 26. Effect of time of application of clopyralid for control of vetch and effect on flowering in lowbush blueberries 27. Effect of time of fall pruning on growth and productivity of blueberries and evaluation of infrared burner to prune blueberries 28. Evaluation of infrared burner for selective seedling weed control 29. Evaluation of pressurized rope wick Wick Master wiper for treating weeds growing above lowbush blueberries 30. Blueberry Extension Education Program Base 31. Blueberry ICM program for Hancock County 32. Composting blueberry processing waste 33. Hexazinone ground water survey 34. Investigations of Lowbush Blueberry Fruit bud Cold-hardiness 35. Design, Fabrication, and Testing of an Experimental Sterilizer for Blueberry Field

Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases

BACKGROUND: Preclinical data suggest that sunitinib enhances the efficacy of radiotherapy. We tested the combination of sunitinib and hypofractionated image-guided radiotherapy (IGRT) in a cohort of patients with historically incurable distant metastases. METHODS: Twenty five patients with oligometastases, defined as 1-5 sites of active disease on whole body imaging, were enrolled in a phase II trial from 2/08 to 9/10. The most common tumor types treated were head and neck, liver, lung, kidney and prostate cancers. Patients were treated with the recommended phase II dose of 37.5 mg daily sunitinib (days 1-28) and IGRT 50 Gy (days 8-12 and 15-19). Maintenance sunitinib was used in 33% of patients. Median follow up was 17.5 months (range, 0.7 to 37.4 months). RESULTS: The 18-month local control, distant control, progression-free survival (PFS) and overall survival (OS) were 75%, 52%, 56% and 71%, respectively. At last follow-up, 11 (44%) patients were alive without evidence of disease, 7 (28%) were alive with distant metastases, 3 (12%) were dead from distant metastases, 3 (12%) were dead from comorbid illness, and 1 (4%) was dead from treatment-related toxicities. The incidence of acute grade ≥ 3 toxicities was 28%, most commonly myelosuppression, bleeding and abnormal liver function tests. CONCLUSIONS: Concurrent sunitinib and IGRT achieves major clinical responses in a subset of patients with oligometastases. TRIAL REGISTRATION: ClinicalTrials.gov NCT00463060

Patient engagement in designing, conducting, and disseminating clinical pain research : IMMPACT recommended considerations

The consensus recommendations are based on the views of IMMPACT meeting participants and do not necessarily represent the views of the organizations with which the authors are affiliated. The following individuals made important contributions to the IMMPACT meeting but were not able to participate in the preparation of this article: David Atkins, MD (Department of Veterans Affairs), Rebecca Baker, PhD (National Institutes of Health), Allan Basbaum, PhD (University of California San Francisco), Robyn Bent, RN, MS (Food and Drug Administration), Nathalie Bere, MPH (European Medicines Agency), Alysha Croker, PhD (Health Canada), Stephen Bruehl, PhD (Vanderbilt University), Michael Cobas Meyer, MD, MBS (Eli Lilly), Scott Evans, PhD (George Washington University), Gail Graham (University of Maryland), Jennifer Haythornthwaite, PhD (Johns Hopkins University), Sharon Hertz, MD (Hertz and Fields Consulting), Jonathan Jackson, PhD (Harvard Medical School), Mark Jensen, PhD (University of Washington), Francis Keefe, PhD (Duke University), Karim Khan, MD, PhD, MBA (Canadian Institutes of Health Research), Lynn Laidlaw (University of Aberdeen), Steven Lane (Patient-Centered Outcomes Research Institute), Karen Morales, BS (University of Maryland), David Leventhal, MBA (Pfizer), Jeremy Taylor, OBE (National Institute for Health Research), and Lena Sun, MD (Columbia University). The manuscript has not been submitted, presented, or published elsewhere. Parts of the manuscript have been presented in a topical workshop at IASP World Congress on Pain in Toronto, in 2022.Peer reviewedPublisher PD